Jade Biosciences (JBIO) Preferred Stock Liabilities (2024 - 2025)

Jade Biosciences (JBIO) posted Preferred Stock Liabilities of $2000.0 for Q1 2025, little changed on a QoQ basis from $2000.0 in Q4 2024.

Jade Biosciences (JBIO) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends

Jade Biosciences' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $2000.0 for Q1 2025.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $2000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $2000.0 (changed N/A YoY) and the FY2024 annual result came in at $2000.0, changed N/A from the prior year.
Preferred Stock Liabilities was $2000.0 for Q1 2025 at Jade Biosciences, roughly flat from $2000.0 in the prior quarter.
Across five years, Preferred Stock Liabilities topped out at $2000.0 in Q2 2024 and bottomed at $2000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Jade Biosciences	16.25 Mn	16.25 Mn	-	-

Download Data